Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|June 13, 2022

Spectrum Chemical Strikes Buffers Distribution Deal with ANGUS Chemical Company

The deal will see Spectrum market and distribute ANGUS’ biologics grade buffers in the United States and Canada.

Spectrum Chemical, a provider of fine chemicals, laboratory equipment, and supplies, announced a new distribution arrangement on June 9, 2022 with ANGUS Chemical Company, a specialty ingredients manufacturer. The deal will see Spectrum market and distribute ANGUS’ tris(hydroxymethyl)aminomethane (TRIS) buffers in the United States and Canada.

According to a company press release, Spectrum will work with the TRIS AMINO Advanced Crystal and BIS-TRIS biologics grade buffers. These products are used as buffering agents in cell culture and bioprocessing applications and in the purification of biological molecules in downstream processing.

“The addition of these essential ANGUS-branded TRIS and TRIS derivative products to our product offering broadens our capability to deliver best-in-class solutions to our biopharmaceutical and life sciences research customers,” said Jim Luchsinger, vice-president, business development, Spectrum Chemical, in the press release. “We are committed to delivering the fullest range of high-quality chemicals necessary for every bioprocessing stage, from development through commercialization.”

“Through Spectrum Chemical’s deep experience in serving the U.S. and Canadian research markets, we look forward to enhancing our supply and delivery capabilities for customers in the region supported by ANGUS’ commitment to providing 100% traceability and the most secure, sustainable supply of these essential chemistries,” said Doug Ward, North American sales director, ANGUS, in the press release.

Source: Spectrum Chemical


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.